REGATAGastroprotective Effects of Rebamipide, Pantoprazole, and Their Combination in AF Patients on DOACs

This study focuses on patients with atrial fibrillation, a heart condition that causes an irregular heartbeat, and who also have a moderate to high risk of developing blood clots. These patients are either currently taking direct oral anticoagulants (DOACs), medications that prevent blood clots, or they need to start taking them. The study also includes patients who need gastroprotection, which helps protect the stomach from issues like ulcers and inflammation. The main goal is to test the effectiveness of a drug called Rebamipide in protecting the stomach, compared to another drug called Pantoprazole and a combination of both. This research is important as it aims to find the best way to protect the stomach while also preventing blood clots in patients with atrial fibrillation. During the study, patients will be randomly assigned to one of three groups. One group will receive standard therapy along with Rebamipide, another group will receive standard therapy and Pantoprazole, and the last group will receive standard therapy, Rebamipide, and Pantoprazole. The study will last up to 24 weeks and include four visits. At each visit, the patients will have a physical examination, their blood pressure and heart rate will be measured, and any side effects will be checked. Additionally, the patients will answer questions about their symptoms and have blood and stool tests. The study will look at whether patients experience any stomach-related issues, such as bleeding, ulcers, or severe discomfort, to determine the effectiveness of each treatment.